Drug Trial Radar · NCT04114539
Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Oct 4, 2019
Primary completion
Nov 11, 2022
Study completion Nov 11, 2022
Sponsor
- Lead sponsor
- Emalex Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.
Conditions
- Tourette Syndrome in Children
- Tourette Syndrome in Adolescence
Interventions
EcopipamDrug
Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Their Relationship (Unrelated, Possibly Related, or Probably Related)Time frame: From start of study drug administration until 30 days after last dose (Up to Month 13)
- Change From Baseline in Hematology Parameters: Basophils to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: Eosinophils to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: ErythrocytesTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: HematocritTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: HemoglobinTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: Leukocytes and PlateletsTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: Lymphocytes to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: Monocytes to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
- Change From Baseline in Hematology Parameters: Neutrophils to Leukocytes Ratio Reported in Percentage of CellsTime frame: Baseline up to Month 12
- Change From Baseline in Serum Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Lactase DehydrogenaseTime frame: Baseline up to Month 12
- Change From Baseline in Serum Chemistry Parameters: Albumin, Globulin and ProteinTime frame: Baseline up to Month 12
- Change From Baseline in Serum Chemistry Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium, Sodium, Triglyceride and Urea NitrogenTime frame: Baseline up to Month 12
- Change From Baseline in Serum Chemistry Parameters: Bilirubin, Creatinine and Direct BilirubinTime frame: Baseline up to Month 12
- Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline up to Month 12
- Change From Baseline in Vital Signs Parameter: Diastolic Blood Pressure and Systolic Blood PressureTime frame: Baseline up to Month 12
- Change From Baseline in Vital Signs Parameter: Pulse RateTime frame: Baseline up to Month 12
- Change From Baseline in Vital Signs Parameter: Body Mass Index [BMI]Time frame: Baseline up to Month 12
- Change From Baseline in Vital Signs Parameter: HeightTime frame: Baseline up to Month 12
- Change From Baseline in Vital Signs Parameter: WeightTime frame: Baseline up to Month 12
- Change From Baseline in Electrocardiogram (ECG) Values Parameters: Aggregate PR Interval, Aggregate QRS Duration, Aggregate QT Interval, and Aggregate QTc IntervalTime frame: Baseline to Month 12
- Number of Participants With Clinically Significant Abnormal Physical Examination FindingsTime frame: Baseline up to Month 12
Locations
65 sites in 5 countries. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
Advanced Research Center Inc.
Anaheim, California
UCLA
Los Angeles, California
PCSD-Feighner Research
San Diego, California
Syrentis Clinical Research
Santa Ana, California
Yale School of Medicine
New Haven, Connecticut
Sarkis Clinical Trials
Gainesville, Florida
Northwest Florida Clinical Research Group, LLC
Gulf Breeze, Florida
Research in Miami Inc.
Hialeah, Florida
University of Miami
Miami, Florida
MedBio Trials
North Miami, Florida
APG Research LLC
Orlando, Florida
University of South Florida
St. Petersburg, Florida
Pediatric Epilepsy and Neurology Specialists
Tampa, Florida
Pediatric Neurology, PA
Winter Park, Florida
Rare Disease Research, LLC
Atlanta, Georgia
Meridian Clinical Research
Savannah, Georgia
Rush University Medical Center
Chicago, Illinois
The University of Chicago Hospitals
Chicago, Illinois
AMR - Baber Research Inc.
Naperville, Illinois
Psychiatric Associates
Overland Park, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Michigan Clinical Research Institute PC
Ann Arbor, Michigan
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan
Helen DeVos Children's Hospital / Spectrum Health Medical Group
Wyoming, Michigan
St. Charles Psychiatric Associates dba Midwest Research Group
Saint Charles, Missouri
Movement Disorders Center
St Louis, Missouri
Alivation Research, LLC
Lincoln, Nebraska
Center for Psychiatry and Behavioral Medicine Inc.
Las Vegas, Nevada
The NeuroCognitive Institute
Mount Arlington, New Jersey
Clinical Research Center of NJ
Voorhees Township, New Jersey
New York Neurology Associates P.C
New York, New York
Hapworth Research Inc.
New York, New York
Mount Sinai School of Medicine
New York, New York
Mood Disorders Consulting Medicine PLLC
New York, New York
Finger Lakes Clinical Research
Rochester, New York
Quest Therapeutics of Avon Lake
Avon Lake, Ohio
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.